BioCryst (BCRX) Receives a Hold from Needham

Needham analyst Serge Belanger maintained a Hold rating on BioCryst (BCRXResearch Report) today. The company’s shares closed last Thursday at $12.52, close to its 52-week high of $14.24.

According to, Belanger is a 4-star analyst with an average return of 6.0% and a 47.2% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Collegium Pharmaceutical, and KalVista Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioCryst with a $15.33 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $14.24 and a one-year low of $3.30. Currently, BioCryst has an average volume of 5.36M.

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BCRX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.